Bank of New York Mellon Corp lowered its position in shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) by 0.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,852,708 shares of the biopharmaceutical company’s stock after selling 6,776 shares during the period. Bank of New York Mellon Corp owned approximately 0.83% of Alexion Pharmaceuticals worth $227,030,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in ALXN. Cornerstone Advisors Inc. increased its position in Alexion Pharmaceuticals by 47.4% in the third quarter. Cornerstone Advisors Inc. now owns 964 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 310 shares in the last quarter. NEXT Financial Group Inc increased its position in Alexion Pharmaceuticals by 66.1% in the second quarter. NEXT Financial Group Inc now owns 1,106 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 440 shares in the last quarter. Bellwether Investment Group LLC purchased a new position in Alexion Pharmaceuticals during the second quarter worth $172,000. Charlemagne Capital Ltd. purchased a new position in Alexion Pharmaceuticals during the second quarter worth $191,000. Finally, Evercore Wealth Management LLC increased its position in Alexion Pharmaceuticals by 5.0% in the second quarter. Evercore Wealth Management LLC now owns 1,735 shares of the biopharmaceutical company’s stock worth $203,000 after buying an additional 83 shares in the last quarter. 94.85% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) opened at 122.59 on Thursday. The stock has a 50 day moving average price of $122.56 and a 200-day moving average price of $128.72. Alexion Pharmaceuticals Inc. has a one year low of $110.56 and a one year high of $193.45. The stock has a market capitalization of $27.48 billion, a P/E ratio of 74.75 and a beta of 1.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.04 by $0.19. The business earned $799 million during the quarter, compared to analyst estimates of $787.07 million. Alexion Pharmaceuticals had a return on equity of 10.58% and a net margin of 12.46%. The business’s revenue was up 19.9% compared to the same quarter last year. During the same period in the prior year, the business earned $1.16 earnings per share. Analysts anticipate that Alexion Pharmaceuticals Inc. will post $4.64 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and republished in violation of US & international copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2016/12/01/alexion-pharmaceuticals-inc-alxn-shares-sold-by-bank-of-new-york-mellon-corp.html.

Several research firms have recently commented on ALXN. Piper Jaffray Cos. set a $176.00 price objective on Alexion Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, November 6th. Vetr downgraded Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $150.62 price objective on the stock. in a research note on Wednesday, August 3rd. Leerink Swann reaffirmed an “outperform” rating and issued a $211.00 price objective on shares of Alexion Pharmaceuticals in a research note on Wednesday. Zacks Investment Research cut Alexion Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 2nd. Finally, Deutsche Bank AG assumed coverage on Alexion Pharmaceuticals in a research report on Thursday, November 3rd. They set a “buy” rating and a $164.00 target price for the company. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $173.59.

In related news, Director Leonard Bell sold 1,300 shares of the stock in a transaction that occurred on Monday, October 31st. The stock was sold at an average price of $135.28, for a total value of $175,864.00. Following the completion of the transaction, the director now directly owns 406,589 shares in the company, valued at $55,003,359.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Julie O’neill sold 650 shares of the stock in a transaction that occurred on Friday, September 2nd. The stock was sold at an average price of $126.29, for a total value of $82,088.50. Following the completion of the transaction, the executive vice president now owns 35,384 shares of the company’s stock, valued at $4,468,645.36. The disclosure for this sale can be found here. 4.41% of the stock is owned by insiders.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.